Alterola Biotech, Inc. Reports Earnings Results for the Second Quarter Ended March 31, 2019
February 24, 2021 at 05:05 pm EST
Share
Alterola Biotech, Inc. announced earnings results for the second quarter ended March 31, 2019. For the second quarter, the company announced operating loss was USD 39,364 compared to USD 1,255 a year ago. Net loss was USD 39,364 compared to USD 5,880 a year ago. For the half year, operating loss was USD 91,751 compared to USD 2,505 a year ago. Net loss was USD 92,000 compared to USD 11,755 a year ago.
Alterola Biotech, Inc. is a pharmaceutical company. The Company is engaged in the development of cannabinoid, cannabinoid-like, and non-cannabinoid pharmaceutical active pharmaceutical ingredients (APIs); pharmaceutical medicines made from cannabinoid, cannabinoid-like, and non-cannabinoid APIs; and European food approval of cannabinoid-based, cannabinoid-like, and non-cannabinoid ingredients and products. The Company has three areas of focus: development of regulated pharmaceuticals (human and animal health) and regulated food products; production of APIs and food-grade ingredients; and formulation, and drug delivery, providing bioavailability, solubility, and stability. It also focuses on developing new medicines from various sources, including botanical, traditional chemical synthesis, and biosynthetic methodologies. Its wholly owned subsidiaries include ABTI Pharma Ltd, Phytotherapeutix Ltd, and Ferven Ltd.
ALTEROLA BIOTECH, INC. 